MedTrace Logo

Safety Profile of Hydroxyethyl Starch

NCT01304433 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1000

Last updated 2011-10-28

No results posted yet for this study

Summary

The study is primarily aimed to collect further data on the safety of the investigational product in a large patient population when used in routine clinical practice in the Asian-Pacific region.

Conditions

  • Plasma Volume Replacement

Interventions

DRUG

Venofundin 6% / Tetraspan 6%

Venofundin 6% / Tetraspan 6%

Sponsors & Collaborators

  • B. Braun Melsungen AG

    lead INDUSTRY

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-01-31
Primary Completion
2011-05-31
Completion
2011-05-31

Countries

  • China
  • Malaysia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01304433 on ClinicalTrials.gov